Zoetis Inc. with price, financials, news flow, and insider context in one page.
Zoetis Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where ZTS sits inside Healthcare and Drug Manufacturers - Specialty & Generic, and the key financial markers that matter before moving into a fuller research workflow.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
This page is structured for research context, not a trade call. It gives you a clean read on where ZTS sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 2.26B | 601M | 291M |
| Q4 2025 | 2.39B | 603M | 732M |
| Q3 2025 | 2.4B | 721M | 805M |
| Q2 2025 | 2.46B | 718M | 409M |
The attacks come as the United States and Iran are supposed to be engaging in a 60-day ceasefire as they attempt to work toward a resolution.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Zoetis Inc. (ZTS) — questions investors ask
What is the current stock price of Zoetis Inc. (ZTS)?
Zoetis Inc. (ZTS) is trading at $76.09, down 2.22% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Zoetis Inc.'s market capitalization?
Zoetis Inc. has a market capitalization of about 31.9B, derived from the latest share price and shares outstanding.
When is Zoetis Inc.'s next earnings date?
Zoetis Inc. is next expected to report earnings on Aug 6, 2026. The ZTS earnings page tracks the estimate and reporting history.
What is Zoetis Inc.'s P/E ratio?
Zoetis Inc. trades at a forward price-to-earnings ratio of 10.26 — one measure of how the market is pricing its future earnings.
What is ZTS's 52-week trading range?
Over the past 52 weeks, ZTS has traded between $72.38 and $161.77.
What sector is Zoetis Inc. in?
Zoetis Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry.
Does Zoetis Inc. pay a dividend?
Zoetis Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for ZTS?
The mean analyst price target for ZTS is $124.00, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This ZTS page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.